Diag2Tec is pleased to announce €400,000 in European funding for our MOCLAM project « Multi-Omics Characterization of Acute Myeloid Leukemia and its Microenvironment » under the FEDER–FSE+ 2021–2027 program, managed by the Region Occitanie. With a total budget of €911,000, the project runs from December 2025 to December 2028.

MOCLAM aims to better understand why leukemia cells resist to targeted therapies. The project will explore the diversity of leukemia cells and their interactions within the microenvironment via Multiomics studies on primary patient samples with the use of proteomic, metabolic, clinical and single cell transcriptomic data.

With integrated bioinformatics analyses and translational validation, MOCLAM ambition is to identify biomarkers that predict treatment response, and new cell-surface targets for immunotherapy. These advances will support the development of translational services at Diag2Tec, helping biotechnology and pharmaceutical companies to evaluate innovative therapies.